Vaping-Associated Lung Injury: Clinical Presentation
E-cigarette or vaping product use-associated lung injury (EVALI) typically presents with a triad of respiratory symptoms (82-87%), gastrointestinal symptoms (77%), and constitutional symptoms (87%), requiring hospitalization in 94% of cases.
Core Clinical Features
The presentation of EVALI is characterized by multiple organ system involvement, not just isolated lung injury 1, 2:
Respiratory Manifestations (Present in 82-87% of cases)
- Shortness of breath/dyspnea (81-83% of patients) - most common respiratory complaint
- Cough (77%)
- Chest pain
- Progressive hypoxia leading to respiratory failure in severe cases 3, 2
Gastrointestinal Symptoms (Present in 77% of cases)
- Nausea and vomiting (75%)
- Abdominal pain (57%)
- These GI symptoms are critical diagnostic clues and occur in over half of patients, distinguishing EVALI from typical pneumonia 1, 2
Constitutional Symptoms (Present in 87% of cases)
- Fever (78-80%) - nearly universal finding
- Fatigue
- General malaise 2
Less Common Presentations
- Neurological symptoms (15%) including headache
- Some patients (35%) may present without respiratory symptoms initially, making diagnosis challenging 1
Disease Severity and Outcomes
The clinical severity varies dramatically but trends toward serious illness 4:
- Hospitalization required: 94.4% of diagnosed cases
- ICU admission: 35.7% of hospitalized patients
- Mortality: 0.9% overall (52 deaths reported among 2,409 cases as of December 2019)
- Rehospitalization: 2.7% within median 4 days of discharge 4
High-Risk Patient Characteristics
Patients at increased risk for severe outcomes and death include 4:
- Older age (median age of deaths: 54 years vs. 23 years for uncomplicated cases)
- Cardiac disease
- Chronic pulmonary disease (COPD, obstructive sleep apnea)
- Diabetes
- 70.6% of rehospitalized patients and 83.3% of deaths had ≥1 chronic condition
Radiological Findings
Imaging is universally abnormal in EVALI 5, 2:
- Bilateral pulmonary involvement (98.1%)
- Ground-glass opacities (94.9%) - hallmark finding
- Consolidations with or without ground-glass changes
- Pneumomediastinum and subcutaneous emphysema can occur as complications 6
Laboratory Findings
- Leukocytosis with elevated inflammatory markers (common)
- Extensive infectious workup typically negative 3, 5
Temporal Pattern
Most patients report vaping for >3 months prior to symptom onset, with symptoms developing over hours to days 2. The acute presentation can mimic severe pneumonia or acute respiratory distress syndrome.
Critical Diagnostic Pitfall
EVALI is a diagnosis of exclusion 6, 5. The key is obtaining a detailed vaping history within the previous 90 days while simultaneously ruling out infectious causes, autoimmune conditions, and vasculitis. The presence of prominent GI symptoms alongside respiratory complaints in a young, previously healthy patient with vaping history should immediately raise suspicion for EVALI rather than typical community-acquired pneumonia.
The multisystem nature of EVALI—particularly the high frequency of GI symptoms—suggests this is not purely a lung injury but rather a systemic toxic exposure syndrome 1. This broader understanding is essential for early recognition, as 35% of patients may not initially present with respiratory complaints.